Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study
Leukemia and Lymphoma, ISSN: 1029-2403, Vol: 64, Issue: 1, Page: 130-139
2023
- 10Citations
- 9Usage
- 21Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations10
- Citation Indexes10
- 10
- Usage9
- Abstract Views5
- Downloads4
- Captures21
- Readers21
- 21
Article Description
The multicohort phase 1b KEYNOTE-013 study (NCT01953692) evaluated the safety and efficacy of pembrolizumab in patients with relapsed or refractory NHL who were ineligible for or failed hematopoietic cell transplantation (HCT). Patients received pembrolizumab (cohort 4) or pembrolizumab plus lenalidomide (cohort 5). Primary end points were safety and objective response rate (ORR) per IWG 2007 criteria. Cohort 4 included 89 patients. ORR was 22% (19/86; 90% CI 15–31; 10 CR, nine PR); ORRs by disease type were 48% (10/21), 10% (2/20), 12% (5/41), and 50% (2/4), for PMBCL, FL, DLBCL, and ‘other’ NHL, respectively. Toxicity was as predicted. Cohort 5 included 19 patients. ORR was 39% (90% CI 20–61; four CR, three PR). Hematologic toxicities were the most common treatment-related AEs. In conclusion, pembrolizumab following HCT ineligibility/failure confirms prior experience in PMBCL but not with NHL subtypes in this study. Additional analyses in DLBCL may not be warranted.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85142278083&origin=inward; http://dx.doi.org/10.1080/10428194.2022.2136956; https://clinicaltrials.gov/ct2/show/NCT01953692; http://www.ncbi.nlm.nih.gov/pubmed/36398795; https://www.tandfonline.com/doi/full/10.1080/10428194.2022.2136956; https://digitalcommons.wustl.edu/oa_4/3440; https://digitalcommons.wustl.edu/cgi/viewcontent.cgi?article=4432&context=oa_4; https://institutionalrepository.aah.org/advocategme/93; https://institutionalrepository.aah.org/cgi/viewcontent.cgi?article=1094&context=advocategme; https://dx.doi.org/10.1080/10428194.2022.2136956
Informa UK Limited
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know